Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $78.32 million. The enterprise value is $45.93 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 44.00 million shares outstanding. The number of shares has increased by 18.71% in one year.
| Current Share Class | 44.00M |
| Shares Outstanding | 44.00M |
| Shares Change (YoY) | +18.71% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 13.52% |
| Owned by Institutions (%) | 16.32% |
| Float | 35.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.53, with a Debt / Equity ratio of 0.34.
| Current Ratio | 9.53 |
| Quick Ratio | 9.00 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -83.18% and return on invested capital (ROIC) is -27.78%.
| Return on Equity (ROE) | -83.18% |
| Return on Assets (ROA) | -18.82% |
| Return on Capital (ROIC) | -27.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $131,000 in taxes.
| Income Tax | 131,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +62.56% in the last 52 weeks. The beta is 0.63, so QNCX's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +62.56% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 47.18 |
| Average Volume (20 Days) | 280,911 |
Short Selling Information
The latest short interest is 2.17 million, so 4.94% of the outstanding shares have been sold short.
| Short Interest | 2.17M |
| Short Previous Month | 1.79M |
| Short % of Shares Out | 4.94% |
| Short % of Float | 6.15% |
| Short Ratio (days to cover) | 30.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.90M |
| Pretax Income | -30.20M |
| Net Income | -53.26M |
| EBITDA | -31.43M |
| EBIT | -31.90M |
| Earnings Per Share (EPS) | -$1.25 |
Full Income StatementBalance Sheet
The company has $47.85 million in cash and $15.45 million in debt, giving a net cash position of $32.40 million or $0.74 per share.
| Cash & Cash Equivalents | 47.85M |
| Total Debt | 15.45M |
| Net Cash | 32.40M |
| Net Cash Per Share | $0.74 |
| Equity (Book Value) | 44.93M |
| Book Value Per Share | 1.04 |
| Working Capital | 46.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.43 million and capital expenditures -$148,000, giving a free cash flow of -$30.58 million.
| Operating Cash Flow | -30.43M |
| Capital Expenditures | -148,000 |
| Free Cash Flow | -30.58M |
| FCF Per Share | -$0.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |